Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE) is focused on developing therapeutic and diagnostic products designed mainly for disorders in the central nervous system. The company’s robust molecular imaging development program targets the diagnosis of Parkinson’s disease and potentially dementia. Altropane, the company’s lead molecular imaging product candidate, is currently in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes, including Parkinson’s Disease. For further information, visit the Company’s web site at www.alseres.com.